Search

Your search keyword '"Leung G"' showing total 1,185 results
Start Over Author "Leung G"
1,185 results on '"Leung G"'

60. Association of ICAM3 Genetic Variant with Severe Acute Respiratory Syndrome

Author

Chan, Kelvin Y. K., Ching, Johannes C. Y., Xu, M. S., Cheung, Annie N. Y., Yip, Shea-Ping, Yam, Loretta Y. C., Lai, Sik-To, Chu, Chung-Ming, Wong, Andrew T. Y., Song, You-Qiang, Huang, Fang-Ping, Liu, Wei, Chung, P. H., Leung, G. M., Chow, Eudora Y. D., Chan, Eric Y. T., Chan, Jane C. K., Ngan, Hextan Y. S., Tam, Paul, Chan, Li-Chong, Sham, Pak, Chan, Vera S. F., Peiris, Malik, Lin, Steve C. L., and Khoo, Ui-Soon

Published
2007
Full Text
View/download PDF

66. Passive Smoking

Author

Vaidya, Jayant Sharad, Critchley, Julia, Hackshaw, Allan, Glaser, John H., Hedley, A. J., Lam, T. H., McGhee, S. M., Leung, G. M., Pow, M., Milne, Eugene, Thun, Michael J., Davis, Ronald M., Horton, Richard, McKee, Martin, Enstrom, James E., Kabat, Geoffrey C., Tonks, Alison, and Smith, Richard

Published
2003

72. Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: A systematic review of non-randomized studies

Author

Cooper Ma, Leung G, Loniewski K, Arnav Agarwal, Thomas Agoritsas, Chris J. Hong, Vernooij Rwm, Rachel Couban, Brian Y. Hong, Patrick Jiho Hong, Dena Zeraatkar, Ahmed Mm, Dookie Je, and Jason W. Busse

Subjects
medicine.medical_specialty, biology, business.industry, Chronic pain, PsycINFO, Guideline, Pain management, medicine.disease, biology.organism_classification, Discontinuation, Medical cannabis, Medicine, Cannabis, business, Intensive care medicine, Adverse effect
Abstract

ObjectiveTo establish the risk and prevalence of long-term and serious harms of medical cannabis and cannabinoids for chronic pain.DesignSystematic review and meta-analysis.Data sourcesMEDLINE, EMBASE, PsycInfo, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to April 1, 2020.Study selectionNon-randomized studies reporting on harms of medical cannabis or cannabinoids in people living with chronic pain with ≥4 weeks of follow-up.Data extraction and synthesisA parallel guideline panel provided input on the design and interpretation of the systematic review, including selection of adverse events for consideration. Two reviewers, working independently and in duplicate, screened the search results, extracted data, and assessed risk of bias. We used random-effects models for all meta-analyses and the GRADE approach to evaluate the certainty of evidence.ResultsWe identified 39 eligible studies that enrolled 12,143 patients with chronic pain. Very low certainty evidence suggests that adverse events are common (prevalence: 26.0%; 95% CI 13.2 to 41.2) among users of medical cannabis or cannabinoids for chronic pain, particularly any psychiatric adverse events (prevalence: 13.5%; 95% CI 2.6 to 30.6). However, very low certainty evidence indicates serious adverse events, adverse events leading to discontinuation, cognitive adverse events, accidents and injuries, and dependence and withdrawal syndrome are uncommon and typically occur in fewer than one in 20 patients. We compared studies with ConclusionsThere is very low certainty evidence that adverse events are common among people living with chronic pain who use medical cannabis or cannabinoids, but that few patients experience serious adverse events. Future research should compare long-term and serious harms of medical cannabis with other management options for chronic pain, including opioids.Systematic review registrationhttps://osf.io/25bxfWhat is already known on this topicMedical cannabis and cannabinoids are increasingly used for the management of chronic pain.Clinicians and patients considering medical cannabis or cannabinoids as a treatment option for chronic pain require evidence on benefits and harms, including long-term and serious adverse events to make informed decisions.What this study addsVery low certainty evidence suggests that adverse events are common among people living with chronic pain who use medical cannabis or cannabinoids, including psychiatric adverse events, though serious adverse events, adverse events leading to discontinuation, cognitive adverse events, accidents and injuries, and dependence and withdrawal syndrome are uncommon.There is insufficient evidence comparing the harms of medical cannabis or cannabinoids to other pain management options, such as opioids.

Published
2021

76. Silicones and Silicone-Modified Materials

Author

STEPHEN J. CLARSON, JOHN J. FITZGERALD, MICHAEL J. OWEN, STEVEN D. SMITH, James E. Mark, Larry N. Lewis, J. Chojnowski, K. Kaźmierski, M. Cypryk, W. Fortuniak, Anthony C. Dagger, J. Anthony Semlyen, J. D. Kress, P. C. Leung, G. J. Tawa, P. J. Hay, Yu. K. Godovsky, N. N. Makarova, E. V. Matukhina, Ud

Published
2000

77. Inpatient Admissions and Re-Admissions in Medicare Beneficiaries Initiating Umeclidinium/Vilanterol or Tiotropium Therapy

Author

Bogart M, Leung GYH, Cyhaniuk A, and DiRocco K

Subjects
copd, initial maintenance therapy, umeclidinium/vilanterol dual therapy, tiotropium monotherapy, hospital admissions, Diseases of the respiratory system, RC705-779
Abstract

Michael Bogart,1 Gary Yat-Hung Leung,2 Anissa Cyhaniuk,2 Kristi DiRocco3 1Customer Engagement, Value, Evidence and Outcomes (CEVEO) US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2STATinMED Research, Dallas, TX, USA; 3US Medical Affairs, GSK, Collegeville, PA, USACorrespondence: Kristi DiRocco, US Medical Affairs, GSK, 1250 S. Collegeville Road, Collegeville, PA, 19426, USA, Tel +1 610-412-7175, Email kristi.k.dirocco@gsk.comPurpose: Patients with chronic obstructive pulmonary disease (COPD) who are hospitalized are more likely to die from their illness and have increased likelihood of re-admission than those who are not. Subsequent re-admissions further increase the burden on healthcare systems. This study compared inpatient admission rates and time-to-first COPD-related inpatient admission among Medicare beneficiaries with COPD indexed on umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO).Patients and Methods: This retrospective study used the All-Payer Claims Database to investigate hospital admission and re-admission outcomes in Medicare beneficiaries with COPD with an initial pharmacy claim for UMEC/VI or TIO from 1 January 2015 to 28 February 2020. Inpatient admissions, baseline, and follow-up variables were assessed in patients indexed on UMEC/VI and TIO after propensity score matching (PSM), with time-to-first on-treatment COPD-related inpatient admission as the primary endpoint. Re-admissions were assessed among patients with a COPD-related inpatient admission in the 30- and 90-days post-discharge.Results: Post-PSM, 7152 patients indexed on UMEC/VI and 7069 on TIO were eligible for admissions analysis. The mean (standard deviation [SD]) time-to-first COPD-related inpatient admission was 46.71 (87.99) days for patients indexed on UMEC/VI and 44.96 (85.90) days for those on TIO (p=0.06). The mean (SD) number of inpatient admissions per patient was 1.24 (2.92) for patients indexed on UMEC/VI and 1.26 (3.05) for those on TIO (p=0.49). Proportion of patients undergoing re-admissions was similar between treatments over both 30 and 90 days, excluding a significantly lower proportion of patients indexed on UMEC/VI than those indexed on TIO for COPD-related re-admissions for hospital stays of 4– 7 days and 7– 14 days, and all-cause re-admissions for stays of 4– 7 days.Conclusion: Patients with COPD using Medicare in the US and receiving UMEC/VI or TIO reported similar time-to-first inpatient admission and similar proportion of re-admissions.Plain Language Summary: Umeclidinium/vilanterol (UMEC/VI) is associated with improvements in patient outcomes for chronic obstructive pulmonary disease (COPD) versus tiotropium (TIO). Patients with COPD who have hospitalizations have higher healthcare costs and are more likely to be re-hospitalized and die from their illness than those who do not. This study compared hospital admission rates and time to admission among Medicare beneficiaries with COPD treated with UMEC/VI versus TIO.This study used a medical record database to compare hospital admissions and re-admissions, baseline and follow-up variables were compared in patients prescribed with UMEC/VI and TIO from 1 January 2015 to 28 February 2020. Hospital re-admissions were assessed among patients with a COPD-related inpatient admission in the 30 or 90 days after discharge.Patients had similar COPD-related hospitalizations and number of hospital admissions per patient regardless of medication. Proportion of patients undergoing re-admissions was similar between treatments, apart from a lower proportion of patients prescribed UMEC/VI than TIO for COPD-related re-admissions for hospital stays of 4– 7 and 7– 14 days, and all-cause re-admissions for 4– 7 days.Despite expectations that patients receiving UMEC/VI would demonstrate increased time-to-first admission and a lower proportion of re-admissions than those receiving TIO, patients reported similar data irrespective of their prescribed medication. Use of head-to-head comparison with claims data and inability to divide patients based on lung function or clinical symptoms may have decreased chances of detecting any significant difference between the treatments, although these results support current recommendations on use of dual therapy.Keywords: COPD, initial maintenance therapy, umeclidinium/vilanterol dual therapy, tiotropium monotherapy, hospital admissions, hospital re-admissions

Published
2024

82. MN1 C-terminal truncation syndrome is a novel neurodevelopmental and craniofacial disorder with partial rhombencephalosynapsis

Author

Mak, C.C., Doherty, D., Lin, A.E., Vegas, N., Cho, M.T., Viot, G., Dimartino, C., Weisfeld-Adams, J.D., Lessel, D., Joss, S., Li, C., Gonzaga-Jauregui, C., Zarate, Y.A., Ehmke, N., Horn, D., Troyer, C., Kant, S.G., Lee, Y., Ishak, G.E., Leung, G., Pritchard, A. Barone, Yang, S., Bend, E.G., Filippini, F., Roadhouse, C., Lebrun, N., Mehaffey, M.G., Martin, P.M., Apple, B., Millan, F., Puk, O., Hoffer, M.J.V., Henderson, L.B., McGowan, R., Wentzensen, I.M., Pei, S., Zahir, F.R., Yu, M., Gibson, W.T., Seman, A., Steeves, M., Murrell, J.R., Luettgen, S., Francisco, E., Strom, T.M., Amlie-Wolf, L., Kaindl, A.M., Wilson, W.G., Halbach, S., Basel-Salmon, L., Lev-El, N., Denecke, J., Vissers, L.E.L.M., Radtke, K., Chelly, J., Zackai, E., Friedman, J.M., Bamshad, M.J., Nickerson, D.A., Reid, R.R., Devriendt, K., Chae, J.H., Stolerman, E., McDougall, C., Powis, Z., Bienvenu, T., Tan, T.Y., Orenstein, N., Dobyns, W.B., Shieh, J.T., Choi, M., Waggoner, D., Gripp, K.W., Parker, M.J., Stoler, J., Lyonnet, S., Cormier-Daire, V., Viskochil, D., Hoffman, T.L., Amiel, J., Chung, B.H., Gordon, C.T., Mak, C.C., Doherty, D., Lin, A.E., Vegas, N., Cho, M.T., Viot, G., Dimartino, C., Weisfeld-Adams, J.D., Lessel, D., Joss, S., Li, C., Gonzaga-Jauregui, C., Zarate, Y.A., Ehmke, N., Horn, D., Troyer, C., Kant, S.G., Lee, Y., Ishak, G.E., Leung, G., Pritchard, A. Barone, Yang, S., Bend, E.G., Filippini, F., Roadhouse, C., Lebrun, N., Mehaffey, M.G., Martin, P.M., Apple, B., Millan, F., Puk, O., Hoffer, M.J.V., Henderson, L.B., McGowan, R., Wentzensen, I.M., Pei, S., Zahir, F.R., Yu, M., Gibson, W.T., Seman, A., Steeves, M., Murrell, J.R., Luettgen, S., Francisco, E., Strom, T.M., Amlie-Wolf, L., Kaindl, A.M., Wilson, W.G., Halbach, S., Basel-Salmon, L., Lev-El, N., Denecke, J., Vissers, L.E.L.M., Radtke, K., Chelly, J., Zackai, E., Friedman, J.M., Bamshad, M.J., Nickerson, D.A., Reid, R.R., Devriendt, K., Chae, J.H., Stolerman, E., McDougall, C., Powis, Z., Bienvenu, T., Tan, T.Y., Orenstein, N., Dobyns, W.B., Shieh, J.T., Choi, M., Waggoner, D., Gripp, K.W., Parker, M.J., Stoler, J., Lyonnet, S., Cormier-Daire, V., Viskochil, D., Hoffman, T.L., Amiel, J., Chung, B.H., and Gordon, C.T.

Abstract

Contains fulltext : 218289.pdf (Publisher’s version ) (Closed access), MN1 encodes a transcriptional co-regulator without homology to other proteins, previously implicated in acute myeloid leukaemia and development of the palate. Large deletions encompassing MN1 have been reported in individuals with variable neurodevelopmental anomalies and non-specific facial features. We identified a cluster of de novo truncating mutations in MN1 in a cohort of 23 individuals with strikingly similar dysmorphic facial features, especially midface hypoplasia, and intellectual disability with severe expressive language delay. Imaging revealed an atypical form of rhombencephalosynapsis, a distinctive brain malformation characterized by partial or complete loss of the cerebellar vermis with fusion of the cerebellar hemispheres, in 8/10 individuals. Rhombencephalosynapsis has no previously known definitive genetic or environmental causes. Other frequent features included perisylvian polymicrogyria, abnormal posterior clinoid processes and persistent trigeminal artery. MN1 is encoded by only two exons. All mutations, including the recurrent variant p.Arg1295* observed in 8/21 probands, fall in the terminal exon or the extreme 3' region of exon 1, and are therefore predicted to result in escape from nonsense-mediated mRNA decay. This was confirmed in fibroblasts from three individuals. We propose that the condition described here, MN1 C-terminal truncation (MCTT) syndrome, is not due to MN1 haploinsufficiency but rather is the result of dominantly acting C-terminally truncated MN1 protein. Our data show that MN1 plays a critical role in human craniofacial and brain development, and opens the door to understanding the biological mechanisms underlying rhombencephalosynapsis.

Published
2020

89. Infectivity, Transmission, and Pathology of Human-Isolated H7N9 Influenza Virus in Ferrets and Pigs

Author

Zhu, H., Wang, D., Kelvin, D. J., Li, L., Zheng, Z., Yoon, S.-W., Wong, S.-S., Farooqui, A., Wang, J., Banner, D., Chen, R., Zheng, R., Zhou, J., Zhang, Y., Hong, W., Dong, W., Cai, Q., Roehrl, M. H. A., H. Huang, S. S., Kelvin, A. A., Yao, T., Zhou, B., Chen, X., Leung, G. M., M. Poon, L. L., Webster, R. G., Webby, R. J., M. Peiris, J. S., Guan, Y., and Shu, Y.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results